Fatty Liver and High Alkaline Phosphatase

Fatty liver disease can cause high alkaline phosphatase (ALP) levels, though it more commonly raises ALT and AST. ALP is produced by the liver, bile ducts, and bone, so a raised result requires careful interpretation. In metabolic dysfunction-associated steatotic liver disease (MASLD), ALP elevations tend to be modest, and a normal ALP does not exclude the diagnosis. Understanding what drives ALP changes, which other conditions can raise it, and when to seek medical advice is essential for anyone who has received an abnormal liver function test result.

Can a fatty liver cause high alkaline phosphatase levels?

Fatty liver disease can raise ALP, but elevations are usually modest; ALT and AST are more characteristically affected, and a normal ALP does not exclude MASLD.

Fatty liver disease can raise alkaline phosphatase (ALP) levels, although it more commonly elevates other liver enzymes such as alanine aminotransferase (ALT) and aspartate aminotransferase (AST). ALP is produced by several tissues in the body, including the liver, bile ducts, and bone, so a raised result does not automatically point to fatty liver alone. When fat accumulates in liver cells, it can trigger low-grade inflammation and mild disruption to bile flow within the liver, both of which may contribute to ALP rising above the normal reference range.

In metabolic dysfunction-associated steatotic liver disease (MASLD), the current consensus term for what was previously called non-alcoholic fatty liver disease (NAFLD), ALP elevations tend to be modest rather than dramatically high.^[1][2] More pronounced ALP rises are more typical of bile duct obstruction or other liver conditions. That said, if MASLD progresses to metabolic dysfunction-associated steatohepatitis (MASH, previously called non-alcoholic steatohepatitis or NASH) or early fibrosis, liver blood tests including ALP can become more noticeably abnormal.^[1][2] ALP can also remain entirely normal in MASLD, and a normal result does not exclude the diagnosis.

It is important to interpret ALP results in context. A single raised ALP reading does not confirm fatty liver disease, nor does a normal ALP rule it out. Your GP will usually look at the full liver function test (LFT) panel alongside your clinical history, body mass index, and any relevant metabolic risk factors such as type 2 diabetes or high triglycerides before drawing conclusions.

What does alkaline phosphatase measure and why does it matter?

ALP is a cholestatic enzyme concentrated in bile duct cells; raised levels indicate impaired bile flow, and GGT is used alongside it to confirm a liver rather than bone source.

Alkaline phosphatase is an enzyme found in several tissues throughout the body, with the liver and bone being the two most clinically significant sources in adults. ALP is routinely measured as part of a standard liver function test panel, which also includes ALT, AST, gamma-glutamyl transferase (GGT), bilirubin, and albumin. Together, these markers help clinicians assess how well the liver is functioning and whether there is evidence of inflammation, obstruction, or structural damage.

Within the liver, ALP is concentrated in the cells lining the bile ducts. When bile flow is impaired, whether due to a gallstone, inflammation, or a structural problem, ALP leaks into the bloodstream and levels rise. This is why ALP is sometimes described as a cholestatic marker, meaning it is particularly sensitive to problems affecting bile drainage rather than liver cell injury directly.

The normal reference range for ALP varies between laboratories and between age groups. Levels are naturally higher in children and adolescents because of active bone growth, and they can also rise during pregnancy due to placental ALP, sometimes substantially. In adults, a result above the upper limit of the laboratory's reference range warrants further investigation, but the clinical significance depends heavily on which other tests are abnormal and by how much.

Isolated mild ALP elevation with normal ALT, GGT, and bilirubin often points to a bone rather than a liver source. Your GP may request a GGT level alongside ALP, as GGT rises with liver and bile duct disease but not with bone disease.^[6] Where uncertainty remains, additional tests such as bone-specific ALP isoenzymes or 5-prime-nucleotidase can help confirm whether the source is hepatobiliary or skeletal.

How fatty liver disease affects your liver blood tests

Fatty liver most commonly raises ALT and AST; ALP may be mildly elevated in more advanced disease, and NICE recommends FIB-4 scoring as a first-line fibrosis assessment tool.

Fatty liver disease most characteristically raises ALT and AST, the enzymes that reflect liver cell injury, rather than ALP, which reflects bile duct stress. In early or simple steatosis (fat in the liver without significant inflammation), liver blood tests may be entirely normal or show only a mild ALT elevation. This means that a normal LFT panel does not exclude fatty liver disease, and imaging such as an ultrasound scan is often needed to confirm the diagnosis.

When fatty liver progresses to MASH, inflammation becomes more prominent and a broader pattern of LFT abnormality may emerge, potentially including a modest ALP rise alongside elevated ALT, AST, and GGT. GGT is a sensitive but non-specific marker that is frequently raised in both alcohol-related and metabolic liver disease, and may be among the earlier markers to become abnormal in people with alcohol-related fatty liver, though this can vary between individuals.

Key patterns your GP may look for include:

• Raised ALT and AST with ALT typically higher than AST in MASLD^[4][13]

• Raised GGT, especially if alcohol is a contributing factor

• Mildly elevated ALP, more likely if there is associated bile duct involvement or advancing disease

• Low albumin or raised bilirubin, which may suggest more advanced liver impairment

Blood tests alone cannot stage fatty liver disease. NICE guidance (NG49) recommends using the FIB-4 score or NAFLD Fibrosis Score as first-line non-invasive tools to assess the degree of fibrosis.^[10][11] The enhanced liver fibrosis (ELF) test is recommended as a second-line assessment for people with indeterminate or high-risk first-line scores.^[10][11] Specialist referral is considered when scores suggest significant scarring.

What other conditions can raise alkaline phosphatase?

Raised ALP can result from bile duct disease, gallstones, Paget's disease, bone metastases, or osteomalacia; isolated ALP elevation without raised GGT suggests a bone rather than liver source.

Many conditions beyond fatty liver disease can raise ALP, and identifying the underlying cause requires careful clinical assessment rather than relying on a single test result. The most important distinction is between a liver source and a bone source, as both are common in clinical practice.

Liver and bile duct causes of raised ALP include:

• Primary biliary cholangitis (PBC), an autoimmune condition affecting the small bile ducts inside the liver^[8][9]

• Primary sclerosing cholangitis (PSC), which causes inflammation and scarring of the bile ducts

• Gallstones obstructing the common bile duct

• Drug-induced liver injury, including reactions to certain antibiotics and herbal supplements; statins are sometimes listed as a potential cause, but they are generally safe in people with MASLD and provide important cardiovascular benefit, so do not stop any prescribed medicine without first speaking to your GP or pharmacist

• Liver metastases or primary liver tumours

• Alcoholic liver disease

• Infiltrative conditions such as sarcoidosis or hepatic tuberculosis

Bone and other causes include:

• Paget's disease of bone, which can cause very high ALP levels^[7]

• Bone metastases from cancers such as breast or prostate cancer

• Osteomalacia (vitamin D deficiency)

• Hyperparathyroidism

• Physiological rises in pregnancy and adolescence

When ALP is raised in isolation, without a corresponding rise in GGT or other liver markers, a bone cause is more likely. If a bone source is suspected, your GP may also check bone profile, vitamin D, calcium, phosphate, and parathyroid hormone levels. If both ALP and GGT are elevated, liver imaging and further specialist assessment are usually the next steps.

When should you see a GP about abnormal liver function results?

See your GP promptly for any raised ALP result, and seek urgent assessment if you develop jaundice, pale stools, dark urine, or severe abdominal pain.

You should see your GP promptly if you receive a blood test result showing a raised ALP or any other abnormal liver function marker, particularly if you have not already discussed it with a clinician. A single abnormal result does not necessarily indicate serious disease, but it does require follow-up to establish whether it is persistent, worsening, or part of a broader pattern.

Contact your GP as a priority if you have a raised ALP alongside any of the following:

• Yellowing of the skin or whites of the eyes (jaundice)

• Pale or clay-coloured stools, dark urine, or generalised itching (pruritus), which are classic signs of impaired bile flow

• Persistent upper abdominal pain, especially in the right side

• Unexplained weight loss or loss of appetite

• Significant fatigue that is not explained by other causes

• Swelling of the abdomen or legs

• A history of heavy alcohol use, obesity, or type 2 diabetes

For symptoms that develop suddenly and are severe, such as acute jaundice with fever and rigors, seek urgent assessment via NHS 111 or attend your nearest accident and emergency department if you feel very unwell.

If you are managing your weight as part of addressing metabolic risk factors for fatty liver disease, an online consultation with a GPhC-registered pharmacy such as Bolt Pharmacy can provide access to prescriber-led weight management support, with clinically appropriate options considered on an individual basis alongside other lifestyle and medical interventions.

NICE recommends that people with suspected MASLD are assessed for cardiovascular risk and metabolic comorbidities at the same time as their liver health, as these conditions frequently coexist.^[10][11] If you experience a suspected adverse reaction to any medicine, you can report it to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Scientific References

1. A multisociety Delphi consensus statement on new fatty liver disease nomenclature (Rinella et al., Hepatology).
2. A multisociety Delphi consensus statement on new fatty liver disease nomenclature (Rinella et al., Journal of Hepatology).
3. Understanding the evolving nomenclature of steatotic liver disease (Brennan et al., The Lancet Gastroenterology & Hepatology).
4. Predominantly Raised ALP – Primary Care Clinical Referral Criteria (NHS Cornwall).
5. Alkaline phosphatase activity in hepatic tissue and serum (Ogawa H et al.).
6. The use of gamma-glutamyl transpeptidase in distinguishing liver and bone sources of raised alkaline phosphatase (Kampa IS).
7. Paget's disease of bone – Diagnosis.
8. EASL Clinical Practice Guidelines: The diagnosis and management of primary biliary cholangitis.
9. Primary biliary cholangitis (PBC).
10. Metabolic dysfunction-associated steatotic liver disease (MASLD): assessment and management (NG49).
11. MASLD: assessment and management (NG49) – full guideline PDF.
12. MASLD: assessment and management (NG49) – recommendations for research.
13. Draft reflection paper on regulatory requirements for development of medicinal products for chronic non-infectious liver diseases (PBC, PSC, NASH).

Frequently Asked Questions